0000000001070109

AUTHOR

Martin Prázný

showing 7 related works from this author

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diab…

2017

Aims These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes trial (CVOT) results, including those from EMPA-REG OUTCOME®, LEADER®, SUSTAIN™-6 and, most recently, the CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting these newest data to clinical practice. Methods The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method …

lcsh:Diseases of the circulatory (Cardiovascular) systemKeywords: Anti-glycaemic drugs ; Cardiovascular disease ; Renal disease ; Type 2 diabetesmedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and DiabetologyDelphi method610 Medicine & health030209 endocrinology & metabolismReviewType 2 diabetesDisease030204 cardiovascular system & hematologyAnti-glycaemic drugs2705 Cardiology and Cardiovascular MedicineTranslational Research BiomedicalRenal disease03 medical and health sciences0302 clinical medicineMultidisciplinary approachDiabetes mellitusDiabetes MellitusmedicineHumansHypoglycemic AgentsEurope EasternIntensive care medicineExpert TestimonyClinical Trials as Topicbusiness.industryType 2 diabetesCardiovascular diseasemedicine.diseaseExpert groupEuropeEastern european2712 Endocrinology Diabetes and MetabolismTreatment Outcome2724 Internal MedicineCardiovascular Diseaseslcsh:RC666-701Practice Guidelines as TopicCardiology and Cardiovascular MedicinebusinessKidney diseaseCardiovascular Diabetology
researchProduct

MOESM4 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern Eur…

2017

Additional file 4: Table S1. Selected outcomes from SGLT2 inhibitor CVOTs.

researchProduct

MOESM1 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern Eur…

2017

Additional file 1. Round 1 questionnaire.

researchProduct

MOESM2 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern Eur…

2017

Additional file 2. Initial recommendation scoring.

researchProduct

MOESM3 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern Eur…

2017

Additional file 3. Final recommendation scoring.

researchProduct